In vitro assays compare liposomal and free curcumin’s anticancer effects in human cancer cells, indicating better efficacy for liposomal formulation.
Phospholipids derived from plants are promising for drug delivery applications. This study aimed to develop liposomes from cost-effective, plant-derived soy lecithin to enhance the cytotoxicity of curcumin (CUR) against a panel of human cancer cells. The optimized curcumin-loaded liposomes (CUR-Liposomes) were characterized and exhibited a nanoscale size of 105.7 nm, and a high negative zeta potential of -49.9 mV. The key finding from the in vitro cytotoxicity assay was that CUR-liposomes demonstrated significantly enhanced anticancer activity compared to free CUR, as evidenced by lower half maximal inhibitory concentration (IC50) values across all tested cancer cell lines, including multidrug-resistant MCF-7 breast adenocarcinoma (MCF-7/ADR), colon (Caco-2), lung (A549), prostate (PC3), and pancreatic (PANC-1) cancer cells. Notably, this enhanced cytotoxicity was not observed in normal Vero cells, suggesting a favorable selectivity profile. These findings demonstrate that liposomal encapsulation using plant-derived lipids is a viable strategy to improve the therapeutic efficacy and potential selectivity of CUR for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: